Triazole treatment
PreclinicalSmall molecule
Triazole treatment is one of 10 small molecule programs targeting Candidemia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Candidemia
#DrugCompanyPhaseTrials
1Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Eraxis
VVicuron Pharmaceuticals
Phase 3
Vfend
PPrism Pharmaceuticals
Phase 3
Actimmune
HHorizon Therapeutics Ireland DAC
Phase 3
Cancidas
FFresenius Kabi Oncology Ltd.
Phase 3
Isavuconazole
AstellasPhase 3
Interferon-Gamma, Recombinant
RRadboud University Medical Center
Phase 3
APX001
Basilea PharmaceuticaPhase 2
Caspofungin Acetate
Merck & Co.Preclinical
Triazole treatment
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triazole treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon